Follow-on roundup: Achillion, Atara, Threshold
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Threshold Pharmaceuticals Inc. (NASDAQ:THLD) have raised a combined $218.5 million in follow-ons since market close on Wednesday.
Achillion raised $123 million through the sale of 12 million shares at $10.25. Leerink; Deutsche Bank; Wells Fargo; and JMP Securities were underwriters. Achillion proposed the offering after market close on Tuesday, when its shares were valued at $11.48. The stock lost $0.14 to $11.09 on Thursday. On Monday, Achillion said 100% of HCV genotype 1 patients treated with ACH-3102, a pan-genotypic second-generation HCV NS5A protein inhibitor, plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), achieved SVR12 after six weeks of treatment in a Phase II trial (see BioCentury Extra, Feb. 9). ...